延长重组人α-2b干扰素抗乙肝病毒治疗疗程的临床分析  

Clinical Analysis of Prolonged Recombinant Interferon α-2b Treatment against Hepatitis B Virus

作　　者：刘华梅[1] 

机构地区：[1]福建省龙岩市第二医院,福建龙岩364000

出　　处：《中国医学创新》2016年第10期19-22,共4页Medical Innovation of China

摘　　要：目的:通过延长重组人α-2b干扰素疗程提高慢性乙肝患者的应答率。方法:选取本院2009年12月-2013年12月收治的HBe Ag阳性慢性乙型病毒性肝炎患者100例作为研究对象,采用随机数字表法将所选患者分为两组,观察组45例,对照组55例。观察组给予重组人α-2b干扰素600万单位,皮下注射,隔日1次,疗程为18个月;而对照组疗程为12个月。对两组患者进行随访,治疗6个月、治疗12个月、治疗结束时、停药随访6个月、停药随访12个月、停药随访18个月时,观察两组患者的肝功能复常、HBe Ag转阴、HBe Ag/HBe Ab转换、HBVDNA转阴等情况。结果:治疗结束时,观察组肝功能复常率优于对照组,比较差异有统计学意义(P<0.05);两组HBe Ag转阴率、HBe Ag/HBe Ab转换率比较,差异无统计学意义(P>0.05)。随访6、12、18个月,观察组的肝功能复常率、HBVDNA转阴率均优于对照组,比较差异均有统计学意义(P<0.05);随访12、18个月,观察组HBe Ag转阴率、HBe Ag/HBe Ab转换率均高于对照组,比较差异均有统计学意义(P<0.05)。结论:延长重组人α-2b干扰素治疗HBe Ag阳性慢性乙型病毒性肝炎疗程能提高患者的应答率,减少复发率,使患者达到更长期的稳定,延缓病情的进展,减少肝硬化和肝癌的发生。Objective：To improve the response rates of patients with chronic hepatitis B by prolonged treatment of recombinant interferon α-2b.Method：A total of 100 patients with HBe Ag-positive chronic hepatitis B in our hospital from December 2009 to December 2013 were selected as the research objects.They were randomlydivided into the observation group（45 cases） and the control group（55 cases）.The observation group was given subcutaneous injection of 6 million units recombinant interferon α-2b once every other day for 18 months,the control group was given subcutaneous injection of 6 million units recombinant interferon α-2b once every other day for 12 months.All subjects were followed up after the end of treatment.The situation of the recovery of liver function,HBe Ag loss,HBe Ag/HBe Ab seroconversion and clearance of HBVDNA were observed and compared between the two groups 6,12 months after treatment,at the end of the treatment and follow up for 6,12,18 months.Result：At the end of the treatment,the recovery rate of liver function in the observation group was better than that in the control group,the difference was statistically significant（P〈0.05）,the differences in the HBe Ag loss rate and HBe Ag/HBe Ab seroconversion rate between the two groups were not statistically significant（P〉0.05）.After following up 6,12,18 months,the recovery rates of liver function and the clearance rates of HBVDNA of the observation group were better than those of the control group,the differences were statistically significant（P〈0.05）.The HBe Ag loss rates and HBe Ag/HBe Ab seroconversion rates of the observation group were higher than those of the control group after following up for 12 months and 18 months,the differences were statistically significant（P〈0.05）.Conclusion：Prolonged treatment of recombinant interferon α-2b in patients with HBe Agpositive chronic hepatitis B can improve the response rate,decrease the recurrence rate,make patients＇ condition long-term stable,postpone its progressing

关 键 词：重组人Α-2B干扰素 HBeAg阳性慢性乙型病毒性肝炎 应答率 

分 类 号：R512.62[医药卫生—内科学]